Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02031770 · ClinicalTrials.gov registry record · NA

Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease

A NA study, sponsored by University of Colorado, Denver.

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT02031770 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02031770, a NA study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD) and large artery damage is a major factor that contributes to death. Metabolic acidosis is a common complication of CKD resulting from an inability of the diseased kidney to excrete the daily dietary acid load and it is associated with all-cause mortality in patients with CKD. However, the effect of treatment of metabolic acidosis with oral sodium bicarbonate on endothelial dysfunction and arterial stiffness in patients with CKD has not been evaluated. The investigators propose a prospective, randomized, controlled, open-label 14-week crossover pilot study examining the effect of treatment of metabolic acidosis with oral sodium bicarbonate on vascular endothelial function in 20 patients with CKD stage IV with metabolic acidosis.

Interventions

  • OTHER Control
  • DRUG Sodium bicarbonate

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-01
Est. Completion 2016-03
Phase NA

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT02031770

The ClinicalTrials.gov registry entry for NCT02031770 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.

NCT02031770 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02031770 about?

NCT02031770 is a clinical study titled "Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease". Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD) and large artery damage is a major factor that contributes to death. Metabolic acidosis is a common complication of CKD resulting from an inability of the diseased kidney to excrete the daily die...

What is the current status of trial NCT02031770?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2014-01. Estimated completion is 2016-03.

What interventions are being tested in trial NCT02031770?

The interventions under investigation include: Control (OTHER), Sodium bicarbonate (DRUG).

Who is sponsoring clinical trial NCT02031770?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.